- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02655744
Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute
Background. Primary central nervous system lymphoma (PCNSL) is an uncommon disease. Conventional treatment has consisted of either whole brain radiotherapy (WBRT) or methotrexate (MTX)-based combined modality therapy combining chemotherapy and cranial irradiation. The treatment principles at our institute have been quite consistent in the past, sticking to the treatment protocol reported by Memorial Sloan-Kettering Cancer Center in 1990s. No matter what the dosage of MTX is, it is well-established that the addition of chemotherapy to cranial RT significantly improved survival outcomes. However, it was found that delayed treatment-related cognitive sequelae emerged as a significant debilitating complication of combined modality treatment in patients with PCNSL, especially when effective treatment can achieve disease control and better survival rates. Furthermore, the specific contribution of the disease per se and various treatment modalities to cognitive impairment remains to be clarified because the neurotoxic potential of combined modality treatments is difficult to differentiate when each can result in cognitive dysfunctions respectively.
Treatment-related neurotoxicity could be demonstrated by virtue of several meaningful indicators, including neurobehavioral assessments, neuroimaging outcomes, and even measures of quality-of-life (QoL).
Methods. Therefore, this one-year individual research will be a prospective observational cohort study with a longitudinal assessment of neurobehavioral functions, neuroimaging, and quality of life for newly-diagnosed patients with primary CNS lymphoma at our institute. According to our cancer center, it is estimated that there would be around 25 cases of newly-diagnosed primary CNS lymphoma at our institute every year. By virtue of multidisciplinary management and teamwork consisting of neurosurgery, hematology, radiation oncology, neuroimaging expertise, and surgical pathology, investigators will attempt to recruit all potentially eligible patients with newly-diagnosed primary CNS lymphoma. Most importantly, the neuropsychologists will participate in our research project, in an effort to integrate the neurobehavioral outcomes into this prospective study. Accordingly, a battery of neuropsychological measures is used to evaluate neurobehavioral functions for the studied patients. The battery is composed of ten standardized neuropsychological tests, covering four domains sensitive to disease and treatment effects (executive function, attention, verbal memory, psychomotor speed), and QoL questionnaires.
Expected results. This prospective cohort study aims to explore and evaluate patients with PCNSL who are newly-diagnosed by using a standard battery of neurobehavioral functions plus neuroimaging studies. It is anticipated investigators will investigate and correlate neurotoxicity indicators in newly-diagnosed patients with PCNSL who are treated with cranial radiotherapy combined with or without MTX-based chemotherapy according to the multidisciplinary treatment guidelines implemented at a single institute.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Taoyuan, Taiwan, 333
- Recruiting
- Chang Gung Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients must have a histopathologic diagnosis of non-Hodgkin's lymphoma (NHL) by brain biopsy
- A typical MRI/CT scan for primary CNS lymphoma is defined as the presence of hypo, iso, or hyperintense parenchymal contrast-enhancing (usually homogeneously) mass lesion(s)
- Patients must have a normal or negative pre-treatment systemic evaluation including: i. A bone marrow aspirate and biopsy ii. CT scans of the chest, abdomen and pelvis iii. Patients must have adequate bone marrow reserve
- Patients must be HIV-1 negative
- Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment
Exclusion Criteria:
- A past history of major psychiatric disease
- Prior cranial irradiation for any reasons
- Other active primary cancer with the exception of basal cell carcinoma of skin and cervical carcinoma in situ
- Pre-existing immunodeficiency such as renal transplant recipient
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
newly-diagnosed patients with primary CNS lymphoma
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in neurocognitive functions from baseline up to 4 months after completing all courses of chemoradiation.
Time Frame: one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
Neurocognitive assessment including : Trail Making Test. |
one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
The change in memory functions from baseline up to 4 months after completing all courses of chemoradiation.
Time Frame: one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
Neurocognitive assessment including : Word Sequence Learning Test. |
one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
The change in general cognitive functions from baseline up to 4 months after completing all courses of chemoradiation.
Time Frame: one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
Neurocognitive assessment including : Mini Mental Status Examination. |
one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
The change in attention functions from baseline up to 4 months after completing all courses of chemoradiation.
Time Frame: one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
Neurocognitive assessment including : Paced Auditory Serial Addition Test-Revised |
one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
The change in executive functions from baseline up to 4 months after completing all courses of chemoradiation.
Time Frame: one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
Neurocognitive assessment including : Modified Card Sorting Test. |
one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
The change in verbal fluency from baseline up to 4 months after completing all courses of chemoradiation.
Time Frame: one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
Neurocognitive assessment including : Semantic association of verbal fluency. |
one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
The change in Intelligence from baseline up to 4 months after completing all courses of chemoradiation.
Time Frame: one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
Neurocognitive assessment including : Wechsler Adult Intelligence Scale (WAIS-III-R). |
one week before the WBRT course, up to 4 months after completing all courses of chemoradiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The time from the date of recruitment to that of intracranial progression/failure noted on brain MRI
Time Frame: Baseline before the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
Baseline before the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
|
Depression Inventory questionnaires.
Time Frame: Baseline before the WBRT course; one month after completing the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
Questionnaires include: Beck Depression Inventory. |
Baseline before the WBRT course; one month after completing the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
Anxiety Inventory questionnaires.
Time Frame: Baseline before the WBRT course; one month after completing the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
Questionnaires include: Beck Anxiety Inventory. |
Baseline before the WBRT course; one month after completing the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
Self- Evaluation questionnaires.
Time Frame: Baseline before the WBRT course; one month after completing the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
Questionnaires include: National Taiwan University Irritability Scale Self- Evaluation (NTUIS-Self). |
Baseline before the WBRT course; one month after completing the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
Family Evaluation questionnaires.
Time Frame: Baseline before the WBRT course; one month after completing the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
Questionnaires include: National Taiwan University Irritability Scale-Family Evaluation (NTUIS-Family). |
Baseline before the WBRT course; one month after completing the WBRT course; 2 months after completing all courses of chemoradiation, and then 4 months later.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 102-5392B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Central Nervous System Lymphoma
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)United States
-
Ono Pharmaceutical Co. LtdRecruitingPrimary CNS Lymphoma | Refractory Primary Central Nervous System LymphomaUnited States
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingPrimary Central Nervous System Lymphoma | Refractory Central Nervous System Lymphoma | Relapsed Primary Central Nervous System LymphomaChina
-
National Taiwan University HospitalNot yet recruitingPrimary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Chang... and other collaboratorsNot yet recruitingPrimary Central Nervous System Lymphoma (PCNSL)
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)France
-
Curis, Inc.RecruitingRelapsed Primary Central Nervous System Lymphoma | Refractory Hematologic Malignancy | Relapsed Hematologic Malignancy | Refractory Primary Central Nervous System LymphomaUnited States, Spain, France, Czechia, Israel, Italy, Poland
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.Active, not recruitingPrimary Central Nervous System Lymphoma (PCNSL) | Secondary Central Nervous System Lymphoma (SCNSL)United States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingRelapsed or Refractory (R/R) Primary Central Nervous System LymphomaChina
-
James RubensteinIncyte CorporationRecruitingPrimary Central Nervous System Lymphoma | CNS Lymphoma | Secondary Central Nervous System LymphomaUnited States
Clinical Trials on Standard treatment protocol with combined chemoradiation
-
Chang Gung Memorial HospitalNot yet recruitingHodgkin Lymphoma | Non Hodgkin Lymphoma | Mediastinal LymphomaTaiwan
-
Muriel POUBLANCWithdrawnOverall Survival Comparison Between the 2 Arms
-
St. Olavs HospitalNorwegian University of Science and TechnologyNot yet recruiting
-
NHS LothianCompletedRupture of Achilles TendonUnited Kingdom
-
University Hospital Inselspital, BerneRecruitingSepsis | Septic Shock | EndocarditisSwitzerland
-
Aristotle University Of ThessalonikiCompleted
-
Universidad San JorgeMontpellier ClinicCompletedSubacromial ImpingementSpain
-
Instituto Politécnico de LeiriaUniversidade Católica PortuguesaCompleted
-
Harran UniversityCompletedDiabetic Foot Ulcer | WoundTurkey
-
Tianjin Medical University Cancer Institute and...Not yet recruiting